The HRs for death for NIVO + IPI or NIVO + Chemo versus Chemo were < 1, suggesting overall survival advantage irrespective of increasing tumor-cell PD-L1 cutoff values (≥ 1%, ≥ 5%, ≥ 10%; HRs 0.46, 0.45, 0.50 for NIVO + IPI and 0.54, 0.51, 0.54 for NIVO + Chemo, respectively). The gene discussed is CD274; the disease is neoplasm.